Main Therapeutic Uses

Dufalac is a medicinal product containing lactulose, a synthetic disaccharide used primarily for its osmotic laxative properties and its ability to act as a prebiotic. It is utilized in clinical practice for the following conditions:

Treatment of Constipation

The primary use of the medication is to encourage bowel movements in patients suffering from chronic or functional constipation. It works by drawing water into the intestinal lumen, which softens the stool and increases its volume, thereby stimulating peristalsis.

Regulation of Physiological Rhythm

In cases where a regular bowel movement is required for medical reasons, such as the presence of hemorrhoids or following surgical interventions on the colon or anal area, the medication helps maintain a soft stool consistency to minimize discomfort and strain.

Hepatic Encephalopathy

The medication is used in the treatment and prevention of hepatic coma and precoma. In patients with liver failure, it helps reduce the absorption of ammonia and other nitrogenous toxins from the gut into the bloodstream by acidifying the colonic contents and promoting the growth of acidophilic bacteria.

Benefits and Mechanism of Action

The therapeutic effects of the medication are based on its specific interaction with the intestinal flora and its osmotic activity.

• Osmotic Effect: By increasing the osmotic pressure in the colon, it prevents the excessive absorption of water, ensuring that stool remains soft and easier to pass.
• Prebiotic Function: As a prebiotic substance, it serves as a food source for beneficial bacteria, such as Bifidobacterium and Lactobacillus. The fermentation of lactulose by these bacteria produces low-molecular-weight organic acids, which lower the pH of the intestinal environment.
• Systemic Safety: The active substance is not absorbed into the bloodstream in significant amounts. It reaches the colon largely unchanged, where it is metabolized by local microbiota, meaning its action is localized to the gastrointestinal tract.

Who Can and Cannot Use Дюфалак (Lactulose)

Official regulatory labeling strictly defines the population eligibility for Lactulose based on age, physiological status, and underlying medical conditions. The medicine is primarily intended for use in adults and adolescents (aged 14 and over). Use in infants and younger children is classified as exceptional and requires medical supervision.

Contraindications (Who Must Not Use)

Lactulose is contraindicated (absolutely prohibited) for patients with specific conditions, including:

• Galactosaemia or rare hereditary sugar intolerances.
• Actual or suspected gastrointestinal obstruction or digestive perforation.
• Acute inflammatory bowel disease (e.g., severe ulcerative colitis or Crohn's disease).
• Painful abdominal syndromes of undetermined cause.

Conditional Use and Special Populations

Population/Condition	Eligibility Status	Special Consideration
Pregnant/Breastfeeding Women	Eligible	No effects anticipated due to negligible systemic absorption.
Diabetic Patients	Use with Caution	High doses (e.g., for Hepatic Encephalopathy) require consideration due to residual sugars.
Pediatric HE Patients	Use Not Established	Safety and efficacy for treating Hepatic Encephalopathy have not been established in the pediatric population (newborns to 18 years).
Renal/Hepatic Impairment	Eligible	No special dosage recommendations are required.

Interactions with other medicines and products — official regulatory information for Дюфалак (Lactulose)

The official regulatory profile for Lactulose primarily documents interactions that are pharmacodynamic, which relates to the drug's requirement for a specific acidic environment within the colon and its effect on stool consistency.

Category	Officially Documented Interacting Substances
Pharmaceutical Agents	Non-absorbable antacids, Oral anti-infective agents, Other laxatives
Specific Example	Neomycin (as an oral anti-infective agent)

Officially Documented Interaction Statements

• Non-absorbable antacids given concurrently may inhibit the desired lactulose-induced drop in colonic pH, a mechanism that could result in a lack of therapeutic effect.
• Oral anti-infective agents, such as neomycin, are a documented theoretical hazard because they may eliminate the colonic bacteria necessary for Lactulose degradation, potentially preventing the required acidification of colonic contents.
• Co-administration of other laxatives is restricted during the initial treatment phase of portal-systemic encephalopathy (PSE). This is specified in the regulatory label because the resulting loose stools could falsely suggest that an adequate Lactulose dosage has been reached.
• The official prescribing information requires that elderly or debilitated patients receiving Lactulose for more than six months must have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically.

This interaction structure is defined in regulatory documents through the concepts of pharmacodynamic interference and therapeutic management constraints. Restrictions focus on substances that impede the necessary biological conditions or interfere with the accurate monitoring of the drug's intended clinical effect.

The action of the drug is confined primarily to the large intestine and involves three simultaneous, localized mechanistic domains that contribute to the observable physiological consequences.

Osmotic Regulation of Fluid Balance

Because the drug is poorly absorbed, its high concentration within the colon creates an osmotic gradient. This gradient draws water from the surrounding tissues into the intestinal lumen, increasing the contents’ volume and reducing their viscosity. This bulk contributes to the initiation of peristalsis.

Microbial Fermentation and Motility Modulation

Native colonic microbiota metabolize the drug, producing short-chain organic acids. The resulting decrease in pH acts as a local chemical stimulus, inducing peristaltic contractions of the intestinal smooth muscle by modulating Ca^2+ flux, thereby increasing the segment's motility.

pH-Dependent Conversion of Nitrogenous Compounds

The lowered pH facilitates the chemical conversion of absorbable ammonia ( NH3) into non-absorbable ammonium ( NH4^+). This ion trapping sequesters the compound within the gut, limiting the transfer of nitrogenous waste from the intestinal lumen to the circulatory system.

The administration of Дюфалак (Lactulose) involves specific parameters regarding its route, dosage, and frequency. The primary method of use is oral administration as a solution or syrup, though a rectal route (as an enema) is used for the management of severe hepatic encephalopathy.

Dosing Regimens

Dosing varies significantly by condition. For constipation, the typical daily dose for adults ranges from 15 mL to 30 mL (10 g to 20 g lactulose), often taken once daily, with a maximum limit that may be increased up to 60 mL if necessary. For hepatic encephalopathy (HE), the regimen is more intensive, starting with hourly doses of 30 mL to 45 mL (20 g to 30 g lactulose) to induce rapid laxation, which is then followed by a divided maintenance dose taken three or four times per day.

Administration and Special Conditions

The oral solution must be accurately measured using a marked measuring device, and it may be mixed with fluids such as water, juice, or milk to facilitate intake. The dose for HE is adjusted based on patient response, with the procedural goal of producing two to three soft stools daily. Pediatric administration requires specific, lower-range doses, such as 2.5 mL to 10 mL daily for infants. Because the effect is not immediate, 24 to 48 hours may be required to achieve a therapeutic bowel movement. If a dose is missed, the recommended approach is to skip the missed dose if the next scheduled dose is near, rather than doubling up.

Lactulose: Recent Clinical Evidence

Clinical trials have consistently investigated lactulose (the active ingredient in Duphalac) for its role in managing chronic constipation and hepatic encephalopathy (HE). The evidence centers on how this non-absorbable synthetic disaccharide functions as both an osmotic laxative and a mechanism for reducing ammonia absorption.

---

Constipation Studies

• Efficacy: Multiple randomized controlled trials (RCTs) have evaluated lactulose in adult and pediatric populations with chronic functional constipation. Research has shown that treatment with lactulose is often associated with a significant increase in weekly stool frequency and improvement in stool consistency.
• Comparison: Findings from systematic reviews indicate that lactulose demonstrates comparable effectiveness to other bulk-forming and osmotic laxatives, often showing high tolerability in long-term use.

---

Hepatic Encephalopathy (HE)

Lactulose is the established primary treatment for HE, a serious complication of liver disease.

• Mechanism Focus: Studies in this area focus on its ability to reach the colon unchanged, where it is metabolized by gut bacteria. This process lowers the colon’s pH, which is theorized to inhibit the absorption of ammonia into the bloodstream.
• Outcomes: Clinical evidence supports the use of lactulose for both the treatment of acute HE episodes and for the prevention of recurrent (secondary) HE, often referred to as prophylaxis. Trials have demonstrated a consistent association with a reduction in the rate of HE recurrence.

---

Safety Profile

Overall, lactulose is considered to have a favorable safety profile. The most commonly reported side effects across clinical trials are gastrointestinal in nature, including flatulence, abdominal discomfort, and diarrhea, particularly when initiated or at higher doses.

Common questions about Дюфалак (FAQ)

---

Q: How quickly can I expect Дюфалак to start working?

The onset of effect is not immediate. Regulatory information notes that because of how the medicine works in the colon, it may take between 24 and 48 hours to produce the intended bowel movement.

---

Q: Can I mix Дюфалак with water or juice?

Official documentation notes that the solution may be mixed with fluids such as water, juice, or milk to help facilitate intake. Accurate measurement of the prescribed dose is a necessary condition before mixing it with any fluid.

---

Q: Is it normal to feel bloated after starting Дюфалак?

Gastrointestinal effects are commonly reported when beginning treatment. These include temporary gas (flatulence) and abdominal discomfort, which are frequently observed during the first few days of treatment and usually diminish with continued therapy.

---

Q: Is there a maximum time frame for using Дюфалак mentioned in regulatory documents?

Official documents do not typically specify a strict maximum duration for use. However, regulatory guidelines state that patients who receive the medicine for more than six months should have their serum electrolytes (body salts) measured periodically to monitor for potential imbalances.

---

Q: Has the safety of Дюфалак been studied in breastfeeding women?

Regulatory prescribing information indicates that no effects are anticipated on the breastfeeding newborn or infant. This is because the systemic exposure (absorption into the body) of the active ingredient to the mother is negligible.

---

Q: What is the expected timeframe for the full effect of Дюфалак?

The onset of the therapeutic effect can take 24 to 48 hours. Official instructions note that consultation with a healthcare provider is generally recommended if the condition has not improved after 4 to 5 days.

---

Q: Can Дюфалак be used by children?

The medicine is sometimes used in children and infants. However, regulatory documents advise that its use in children under 14 years of age is generally classified as exceptional and requires medical supervision.

---

Q: Is it suitable to use Дюфалак during pregnancy?

Official documentation states that because the systemic exposure (absorption into the body) of the active ingredient is negligible, no effects are anticipated during pregnancy.

---

Q: Are there any known issues with using Дюфалак for a long time?

For patients using the medicine for an extended period, particularly at higher doses, a documented risk is the potential for electrolyte imbalance and dehydration. This can occur if prolonged or excessive diarrhea is experienced.

---

Q: Why do some people say Дюфалак tastes sweet?

The active ingredient itself, lactulose, is a synthetic disaccharide sugar. The product’s composition, according to regulatory documents, also includes small residual amounts of other sugars such as galactose and lactose.

---

Q: Is Дюфалак considered a stimulant laxative?

The medicine is officially classified as an osmotic laxative, a distinct category. Its primary mechanism involves drawing water into the colon, which is different from the pure stimulant laxatives.

---

Q: Does Дюфалак affect the absorption of other medicines?

The official interaction profile mainly discusses substances that affect the colonic environment. However, some regulatory sources note that co-administration with other medicines that speed up intestinal motility may potentially decrease their absorption.

---

Q: Can Дюфалак be taken with food?

Regulatory information confirms the medicine can be taken with or without food. This is because its main mechanism of action takes place in the large intestine and is not dependent on the presence of food in the stomach or small intestine.

---

Q: Is Дюфалак intended for everyday use?

For official indications like chronic constipation and hepatic encephalopathy, the medicine may be used as a long-term treatment, sometimes for many months, under the guidance of a healthcare professional.

---

Q: What is the official designation of Дюфалак (e.g., prescription or over-the-counter)?

The official status of the medicine varies by country and jurisdiction. In some regions, it is available as a prescription-only medicine, while in others, it is available for purchase without a prescription from pharmacies (over-the-counter).

---

Q: Are there different forms or concentrations of Дюфалак available?

The medicine is available as an oral solution or syrup in different concentrations. Some forms are also approved for rectal administration (enema) for specific, severe indications.

---

Q: Can men and women use Дюфалак in the same way?

Dosage is based on age and the condition being treated, not on gender. The regulatory prescribing information outlines regimens for adults and children regardless of gender.

---

Q: What information is available regarding overdosage of Дюфалак?

The documented signs of overdosage are severe abdominal pain and diarrhea. Management involves discontinuing the medicine and correcting any resulting fluid and electrolyte imbalances that may occur.

---

Q: Does taking Дюфалак at a specific time of day change the outcome?

For patients taking a single daily dose, regulatory information often suggests taking the medicine at the same time each day, such as during breakfast, to help establish a consistent routine. However, the timing relative to meals does not affect its core mechanism of action.

---

Q: Does Дюфалак contain any sugar other than lactulose?

Yes, in addition to the active ingredient lactulose (which is a sugar), regulatory information confirms the solution contains small residual amounts of other related sugars, including galactose and lactose.

---

Q: Is it possible for Дюфалак to cause dehydration?

Dehydration is a documented risk associated with the prolonged presence of severe or excessive diarrhea, which is a side effect that may occur when using higher doses. This is related to the loss of fluid and electrolytes.

How to Store and Dispose of Дюфалак (Lactulose)

The storage and disposal of this medicine must comply strictly with official regulatory requirements to maintain product quality and safety.

Official Storage Conditions

Requirement	Specific Condition
Temperature	Store the product below 25 C (77 F).
Protection	The solution must be protected from freezing (Do not freeze).
Container	Keep the medicine in its original container.

Handling and Disposal Rules

To ensure proper stability, the medicine should not be used after the expiry date printed on the label. For safety, always keep the product out of the sight and reach of children.

When disposing of unused or expired product, it must be done according to local requirements for pharmaceutical waste. Do not dispose of this medicine by pouring it into wastewater or mixing it with household trash.